Clinical analysis of prenatal diagnosis, ultrasound findings, and follow-up in 92 Turner mosaic fetuses: a retrospective analysis of 12-year experience Authors: Xiaojin Luo, Hongyan Niu, Yanli Tang, Jinmao Xu, Fei Zhou, Xiaoyi Cong, Shuangwu Li, Yuanyuan Pei, Liang Chang, Weiqiang Liu, Fengxiang Wei Published: 2026 ABSTRACT AbstractObjectiveThis study conducted a retrospective analysis on ultrasound findings, karyotype characteristics, pregnancy outcomes, and follow-up data for 92 fetuses diagnosed with Turner mosaicism. It provides essential clinical data on the prenatal and postnatal outcomes of these cases.MethodsA comprehensive review and analysis were conducted on 92 cases of Turner mosaic fetuses diagnosed by karyotyping, SNP-array, or FISH at the Prenatal Diagnosis Center of Shenzhen Longgang Maternal and Child Health Hospital, a tertiary medical center, between January 2013 and September 2025. The analysis focused on maternal demographic data, types and proportions of mosaic karyotypes, ultrasound findings, pregnancy outcomes, and postnatal follow-up data.ResultsOf 12,855 high-risk pregnancies undergoing amniocentesis, 92 Turner mosaic fetuses ( 0.72%, 92/12855) were identified. The majority (65/92, 70.7%) exhibited X-chromosome aneuploidy mosaicism, most commonly 45,X/46,XX (52 cases). Mosaicism involving structural abnormalities of the X chromosome was observed in 27 cases (29.3%), including eight cases of 45,X/46,X, i(X)(q10). Ultrasonography detected abnormalities in 10 fetuses — three with cardiovascular malformations, two with growth restriction, and one with cystic hygroma — while the remaining 82 cases had no abnormal ultrasound findings. Two cases were notable for complex multi-system anomalies: one with 45,X[24]/46,XX[76] presented with coarctation of the aorta, a horseshoe kidney, and increased nuchal translucency (3.2 mm); another with 46,X, i(X)(q10)[66]/46,XX[24] had a ventricular septal defect, left clubfoot, and bilateral ventricular widening. Of the 92 fetuses with Turner mosaicism, 69 pregnancies were terminated and 23 were continued. Among the 23 continuing pregnancies, one resulted in embryonic arrest, one was subsequently terminated, and one delivered preterm at 34 weeks. Twenty infants were live-born and followed up: three showed delayed language and motor development, one had epilepsy, one had hearing loss, and one exhibited short stature with dry skin. Notably, the abnormal mosaic ratio in all cases with postnatal findings ranged from 20% to 30%.ConclusionThe prenatal phenotype of Turner mosaicism is largely determined by the proportion of abnormal cells and the tissues involved. Clinical decisions should caution against termination for mosaic ratio below 30%, as cases under 10% typically have favorable outcomes. Although prenatal ultrasound findings for Turner mosaicism lack specificity, they may be closely associated with cardiovascular abnormalities and intrauterine growth restriction. After birth, it is crucial to conduct close postnatal monitoring of neurodevelopment for these children.Keywords: Prenatal diagnosis, Turner mosaic, ultrasound findings Introduction Turner syndrome is a chromosomal disorder defined by the partial or complete absence of one X chromosome, with the classic 45,X karyotype being the most common presentation. It affects approximately 1 in 2,000 to 2,500 live female births [1]. Many cases are identified in childhood due to characteristic signs such as short stature, a webbed neck, and cubitus valgus. Additionally, a significant number of cases are diagnosed in gynecological settings where patients typically present with ovarian dysfunction, often manifested as primary or secondary amenorrhea, primary ovarian insufficiency, and infertility [2]. There are various karyotypes in Turner syndrome. The classic 45,X karyotype accounts for 40–50% of cases. Approximately 15–30% are mosaic (e.g., 45,X/46,XX or 45,X/46,XX/47,XXX), and about 10% involve structural abnormalities of the X chromosome. The remaining cases may present with a Y-chromosome component or ring chromosomes [3]. Due to the presence of a 46,XX or other cell line, the clinical manifestations in individuals with Turner mosaic are often milder and more diversity than those in patients with 45,X karyotype [1]. Individuals with mosaic Turner syndrome exhibit a wide spectrum of clinical features. Common manifestations include short stature, ovarian dysfunction, cardiovascular anomalies, and renal malformations [4, 12, 13]. However, the expression of these features is highly variable and non-specific, due to factors such as the degree and tissue distribution of mosaicism, as well as the specific regions of the X chromosome involved [5]. Research indicates that individuals with mosaic Turner syndrome karyotypes (e.g., 45,X/46,XX or 45,X/47,XXX) generally present with a milder phenotypic spectrum and a lower incidence of cardiovascular abnormalities compared to those with a pure 45,X karyotype [6]. Conversely, the presence of a Y-chromosome-containing cell line increases the risk of gonadoblastoma. Furthermore, an association has been observed between Turner mosaic involving a ring X chromosome and intellectual disability [7]. However, the mechanism underlying the correlation between mosaic Turner syndrome and its clinical phenotype remains elusive, imposing a significant burden on patients and their families. Furthermore, while numerous case reports exist on prenatally diagnosed cases, a systematic and comprehensive analysis is lacking. Notably, some prenatally detected mosaic cases show no abnormal clinical manifestations after birth, whereas others present with typical Turner syndrome features or other phenotypes [8]. The scarcity of systematic discussions on the clinical phenotypes, pregnancy outcomes, and long-term prognosis of mosaic Turner syndrome significantly complicates prenatal genetic counseling. This study is based on a relatively large prenatal Turner mosaic fetal cohort and explores its prenatal clinical manifestations, pregnancy outcomes, and follow-up information. It aims to provide more comprehensive clinical data for prenatal diagnosis and clinical consultation. Subjects and Methods Subjects A retrospective analysis was conducted on 92 cases of Turner mosaicism. These cases were prenatally diagnosed by amniocentesis following high-risk indications at the Prenatal Diagnosis Center of Shenzhen Longgang Maternal and Child Health Hospital between January 2013 and September 2025. This analysis concentrated on evaluating ultrasound abnormalities, mosaic karyotypes, pregnancy outcomes, and postnatal follow-up. High-risk indications for prenatal diagnosis in this cohort included: (1) fetal ultrasound anomalies, (2) high-risk non-invasive prenatal testing (NIPT) results, (3) advanced maternal age (≥ 35 years), (4) high-risk serum screening results ( cut-off > 1:270), and (5) a history of adverse pregnancy outcomes. Before undergoing invasive prenatal diagnosis and SNP-array testing, pregnant women were fully informed about the research objectives, experimental procedures, and potential risks, and signed an informed consent form. When pregnant women opted to continue with their pregnancies, telephone follow-ups were conducted to monitor the growth and development of the newborns. This study only included cases with Turner mosaic, excluding cases involving other chromosomal variations. This study involved a retrospective evaluation of human biological samples and was approved by the Ethics Review Committee of Longgang Maternal and Child Health Hospital in Shenzhen (No. LGFYYXLL-028). All procedures followed the principles of informed consent and complied with data protection regulations. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Methods Karyotype analysis Karyotyping was performed on amniotic fluid samples according to standard cytogenetic protocols. Briefly, the samples were cultured in AmnioMAX™-II Complete Medium (Gibco, USA) to promote cell proliferation and maintained in an incubator for 6–8 days, with the duration adjusted based on cell growth. Chromosome preparations were obtained using conventional methods. The metaphase spreads were scanned using an automated system (Leica GSL120, USA). For each specimen, at least 10 metaphase spreads were examined at a resolution of 400–550 bands per haploid set. Chromosome classification and reporting followed the guidelines of the International System for Human Cytogenetic Nomenclature (ISCN). SNP-array analysis Genomic DNA was extracted from uncultured amniotic fluid. The DNA was then hybridized to the Affymetrix CytoScan 750 K Array (Applied Biosystems, Santa Clara, CA) and scanned using the Affymetrix GeneChip Scanner 3000, following the manufacturer’s protocol. The resulting data were analyzed using Chromosome Analysis Suite (ChAS) software version 3.3.1 (Applied Biosystems), with CNVs annotated based on the GRCh37 genome (hg19). According to American College of Medical Genetics and Genomics guidelines, CNVs were classified into five categories: pathogenic, likely pathogenic, benign, likely benign, and variants of uncertain significance. FISH testing Fluorescence in situ hybridization (FISH) was performed on 5 ml of uncultured amniotic fluid. A prenatal chromosome detection kit from Anbiping (Guangzhou, China) was used for hybridization, washing, restaining, and placing the slides under a fluorescence microscope according to the instructions in the manual. Randomly count at least 50 cells per specimen. If more than 90% of cells show normal signals, the sample is considered normal. If abnormal signals are detected, the counting will be extended to 100 cells, and cases where abnormal cells account for more than 10% are classified as mosaicism. Follow-up Telephone follow-ups were conducted within two weeks before and after the expected delivery date provided by the pregnant women. These follow-ups documented any fetal ultrasound abnormalities, whether the pregnancy continued, the mode of delivery, and the phenotypes of the carrier parents after confirming parental origin. After the birth of the child was confirmed, regular telephone follow-ups were conducted every six months to document the child’s postnatal growth and development, focusing on aspects such as language expression. The latest follow-up was conducted on September 15, 2025. The oldest child is 6 years and 5 months old, and the youngest is 18 months old. Results General information From January 2013 to September 2025, amniocentesis was performed on 12,855 pregnant women with high-risk indications, identifying 92 cases of Turner syndrome mosaicism, yielding a detection rate of 0.72% (92/12,855). Prenatally, abnormal ultrasound findings were observed in 10 cases, while the remaining 82 cases showed no abnormal phenotypes. Regarding pregnancy outcomes, 69 cases opted for termination of pregnancy. Among the 23 cases that continued the pregnancy, there was one case of embryonic arrest, one termination of pregnancy, and one premature delivery at 34 weeks of gestation. Follow-up of the 20 live births revealed three cases with delayed language and motor development, and one case each of epilepsy, hearing loss, and short stature with dry skin (Fig. 1). The brief flowchart of this study shows that 92 cases of Turner mosaic were detected among 12,855 high-risk pregnant women, 82 cases showed no ultrasound phenotype, and 10 cases showed ultrasound abnormalities. 69 cases chose to terminate the pregnancy, 23 cases chose to continue the pregnancy, and 20 cases had normal live births Distribution of karyotypes in 92 fetuses of Turner syndrome mosaicism Among the 92 cases of Turner syndrome mosaicism, 65 (70.7%) involved X chromosome aneuploidy. Of these, the majority (n = 52) were 45,X/46,XX, followed by 45,X/46,XY (n = 6), 45,X/47,XXX/46,XX (n = 4), and 45,X/47,XXX (n = 3). The remaining 27 cases (29.3%) featured structural abnormalities of the X chromosome. This subgroup included eight cases of 45,X/46,X, i(X)(q10); three cases each of 46,X, i(X)(q10)/46,XX and 45,X/46,X, r(X)(p11.2q28), with the remaining cases comprising other structural variants (Table 1). Table 1 Karyotype distribution of 92 Turner mosaicsKaryotypingn (%)X aneuploidy mosaics65 (70.7%)45,X/46,XX52 (56.5%)45,X/46,XY6 (6.5%)45,X/47,XXX/46,XX4 (4.3%)45,X/47,XXX3 (3.3%)X structural abnormality mosaics27 (29.3%)45,X/46,X, i(X)(q10)8 (8.7%)46,X, i(X)(q10)/46,XX3 (3.3%)45,X/‌46,X, r(X)‌(p11.2q28)3 (3.3%)45,X/46,X,+mar3 (3.3%)45,X/46,X, del(X)(q25)2 (2.2%)46,X, del(X)(p22.31)/46,XX2 (2.2%)45,X/46,X, del(X)(q26.3)1 (1.1%)45,X/46,X, psu dic(X)(p22.1)1 (1.1%)45,X/46,X, i(X)(q10)/47,X, i(X)(q10)X21 (1.1%)45,X/46,X, der(X)t(1;X)(q24;q25)1 (1.1%)46,X, del(X)(p12)/46,XX1 (1.1%)46,X, del(X)(q12)/46,XX1 (1.1%)Total92 Karyotype distribution of 92 Turner mosaics Prenatal ultrasound features in Turner mosaic fetuses Among the 92 fetuses with Turner syndrome mosaicism, ten (10.9%, 10/92) exhibited abnormal ultrasound findings. The detected ultrasound phenotypes primarily included three cases with cardiovascular malformations ( Two cases of aortic coarctation and one case of ventricular septal defect ), three cases with increased NT, two cases with intrauterine growth retardation, two cases with widened lateral ventricles. Cystic hygroma, a choroid plexus cyst, a horseshoe kidney, left clubfoot, oligohydramnios and polyhydramnios were detected in one case each, respectively. Table 2. One case (karyotype 45,X [24]/46,XX[76]) presented a distinct phenotype, featuring aortic coarctation, a horseshoe kidney, and increased nuchal translucency (3.2 mm) (Fig. 2A–C). Another notable case (karyotype 46,X, i(X)(q10)[66]/46,XX [24]) was also remarkable for multi-organ malformations, including a ventricular septal defect, left clubfoot, and bilaterally widened lateral ventricles (left: 2.22 cm; right: 2.13 cm) (Fig. 2D–F). With the exception of Cases 4 and 5, who continued their pregnancies, the other eight cases with abnormal ultrasound findings opted for pregnancy termination. Table 2Abnormal ultrasound phenotypes in 10 fetuses with Turner mosaicCasekaryotypingUltrasound findings145,X[55]/46,XX[25]Cystic hygroma245,X[24]/46,XX[76]Aortic coarctation、horseshoe kidney、Increased NT (3.2 mm)345,X[36]/47,XXX[44]Aortic coarctation, polyhydramnios445,X[10]/47,XXX[12]/46,XX[78]Choroid plexus cyst545,X[24]/46,XX[76]Increased NT (3.0 mm )645,X[34]/47,XXX[54]Increased NT(2.7 mm ), intrauterine growth retardation746,X, i(X)(q10)[66]/46,XX[24]Ventricular septal defect、left clubfoot,Bilateral widened lateral ventricles845,X[18]/46,X, del(X)(q25)[82]Left kidney deficiency946,X, del(X)(q12)[33]/46,XX[67]Widened lateral ventricles, oligohydramnios1046,X, i(X)(q10)[74]/45,X[6]Intrauterine growth retardation Abnormal ultrasound phenotypes in 10 fetuses with Turner mosaic Ventricular septal defect、left clubfoot, Bilateral widened lateral ventricles Prenatal ultrasound findings from two Turner mosaic fetuses with complex structural abnormalities. A-C A case with the 45,X [24]/46,XX[76] karyotype, demonstrating increased nuchal translucency (3.2 mm) (A), aortic coarctation (B), and a horseshoe kidney (C). D-F A case with the 46,X, i(X)(q10)[66]/46,XX [24] karyotype, showing a ventricular septal defect (D), left clubfoot (E), and bilateral ventriculomegaly (left: 2.22 cm; right: 2.13 cm) (F) Prenatal diagnosis and postnatal follow-up of 23 cases of Turner syndrome mosaicism Among 92 cases of Turner syndrome mosaicism, 23 pregnancies were continued. Karyotype analysis detected Turner mosaicism in 21 of these 23 cases, while SNP‑array identified it in 15 cases. In addition, SNP‑array revealed two cases with deletions in the Xp22.31p22.33 region. However, it failed to detect six cases with a mosaicism level below 10% and two cases of 45,X/47,XXX/46,XX mosaicism. FISH successfully identified all 23 cases of 45,X [10]/47,XXX [12]/46,XX mosaicism. Notably, four of these were confirmed using customized targeted probes designed based on prior results: two from karyotyping (46,X, i(X)(q10)) and two from SNP‑array (Xp22.31p22.33 deletion mosaicism). Moreover, in cases 4 and 11, the mosaicism ratios determined by karyotype were 7.7% and 13%, respectively, whereas FISH yielded higher ratios of 18% and 25%. This discrepancy suggests a possible loss of abnormal cells during cell culture. The distribution of mosaicism ratios was as follows: six cases had a ratio below 10%, 14 cases were between 10% and 30%, and three cases exceeded 30%. Twenty pregnancies resulted in the birth of phenotypically normal infants. The three adverse outcomes included: one case of 45,X [26]/46,XX[74] that ended in embryonic demise at 27 weeks; one case of 45,X [32]/46,XX[68] with preterm delivery at 35 weeks (birth weight 2.0 kg); and one case of 45,X [24]/47,XXX [6]/46,XX[70] that was terminated at 26 weeks due to severe growth retardation and oligohydramnios. During postnatal follow-up, six children exhibited abnormal phenotypes, including epileptic seizures, language/motor developmental delay, hearing impairment, short stature (-2 SD), and dry skin. Notably, none of the six cases with a mosaicism ratio below 10% showed any abnormal clinical phenotypes during follow-up (Table 3). Table 3 Prenatal diagnosis and follow-up of 23 Turner mosaic fetuses who chose to continue pregnancyCaseGWHigh risk / Ultrasound findingsKaryotyping(Ratio %)SNP-array (Ratio %)FISH (Ratio %)Pregnancy outcomeFollow-up information121+ 4NIPT indicates X chromosome reduction45,X[12]/46XX[64] (15.8%)arr[hg19] (X)×1 ~ 2 (15%)Nuc ish (DXZ3)×1[15]/ (DXZ3)×2[85]Live birthNo visible abnormalities219+ 5Adverse pregnancy history ( child with trisomy 21 )45,X[8]/46XX[92] (8.0%)arr[hg19] (X)×2Nuc ish (DXZ3)×1[10]/ (DXZ3)×2[90]Live birthNo visible abnormalities321+ 4NIPT indicates X chromosome reduction45,X[26]/46XX[74] (26.0%)arr[hg19] (X)×1 ~ 2 (25%)Nuc ish (DXZ3)×1[28]/ (DXZ3)×2[72]Embryonic demise(27 weeks)N/A421+ 4High risk of serum screening45,X[7]/46XX[84] (7.7%)arr[hg19] (X)×2Nuc ish (DXZ3)×1[18]/ (DXZ3)×2[82]Live birthNo visible abnormalities521+ 4NIPT indicates X chromosome reduction45,X[18]/46XX[64] (22.0%)arr[hg19] (X)×1 ~ 2 (20%)Nuc ish (DXZ3)×1[25]/ (DXZ3)×2[75]Live birthSeizure at the age of 6 years and 8 months621+ 4AMA45,X[15]/46XX[85] (15.0%)arr[hg19] (X)×1 ~ 2 (15%)Nuc ish (DXZ3)×1[19]/ (DXZ3)×2[81]Live birthNo visible abnormalities721+ 4NIPT indicates X chromosome reduction45,X[21]/46XX[79] (21.0%)arr[hg19] (X)×1 ~ 2 (20%)Nuc ish (DXZ3)×1[22]/ (DXZ3)×2[78]Live birthSpeech & motor delays at 4 years and 5 month old821+ 4AMA, High risk of serum screening45,X[24]/46XX[76] (24.0%)arr[hg19] (X)×1 ~ 2 (25%)Nuc ish (DXZ3)×1[21]/ (DXZ3)×2[79]Live birthNewborn hearing impairment in the right ear921+ 4History of adverse pregnancy45,X[25]/46XX[75] (25.0%)arr[hg19] (X)×1 ~ 2 (28%)Nuc ish (DXZ3)×1[22]/ (DXZ3)×2[78]Live birthSpeech delays at 3 years and 2 month old1021+ 4NIPT indicates X chromosome reduction45,X[32]/46XX[68] (32.0%)arr[hg19] (X)×1 ~ 2 (26%)Nuc ish (DXZ3)×1[35]/ (DXZ3)×2[65]premature birth(34 weeks)Low birth weight (2.0Kg)1119+ 5Increased NT (3.0 mm )45,X[13]/46XX[87] (13.0%)arr[hg19] (X)×1 ~ 2 (18%)Nuc ish (DXZ3)×1[25]/ (DXZ3)×2[75]Live birthNo visible abnormalities1220+ 4AMA45,X[8]/46XX[92] (8.0%)arr[hg19] (X)×2Nuc ish (DXZ3)×1[6]/ (DXZ3)×2[94]Live birthNo visible abnormalities1321+ 5History of adverse pregnancy45,X[7]/46,XY[83] (7.8%)arr[hg19] (X, Y)×1Nuc ish (DXZ3)×1[9]/ (DYZ1, DXZ3)×1[91]Live birthNo visible abnormalities1419AMA45,X[6]/46,XY[85] (6.6%)arr[hg19] (X, Y)×1Nuc ish (DXZ3)×1[8]/ (DYZ1, DXZ3)×1[92]Live birthNo visible abnormalities1522AMA, High risk of serum screening45,X[10]/47,XXX[12]/46,XX[78] (22.0%)arr[hg19] (X)×2Nuc ish (DXZ3)×1[15]/ (DXZ3)×3[22]/(DXZ3)×2[63]Live birthNo visible abnormalities1623+ 3AMA, Choroid plexus cyst45,X[16]/47,XXX[8]/46,XX[76] (24.0%)arr[hg19] (X)×2Nuc ish (DXZ3)×1[18]/ (DXZ3)×3[6]/(DXZ3)×2[76]Live birthNo visible abnormalities1721NIPT indicates X chromosome reduction45,X[24]/47,XXX[7]/46,XX[69] (31.0%)arr[hg19] (X)×1 ~ 2 (28%)Nuc ish (DXZ3)×1[25]/ (DXZ3)×3[15]/(DXZ3)×2[60]TOP(26 weeks)Small for gestational age,oligohydramnios1822AMA45,X[25]/47,XXX[75] (25.0%)arr[hg19] (X)×2 ~ 3 (23%)Nuc ish(DXZ3)×1[28]/ (DXZ3)×3[72]Live birthSpeech delays & motor at 2 years and 2 month olds1919 + 6NIPT indicates X chromosome reduction45,X[16]/47,XXX[84] (16.0%)arr[hg19] (X)×2 ~ 3 (35%)Nuc ish(DXZ3)×1[14]/ (DXZ3)×3[86]Live birthNo visible abnormalities2021History of adverse pregnancy, AMA46,X, i(X)(q10)[9]/46,XX[91] (9.0%)arr[hg19] (X)×246,X.ish del(X)(p11.2)[8]/46,XX[92]Live birthNo visible abnormalities2122AMA46,X, i(X)(q10)[18]/46,XX[82] (18.0%)arr[hg19] Xp11.2p22.33 × 1 ~ 2, Xq11.2q28 × 2 ~ 23 (15%)46,X.ish del(X)(p11.2)[14]/46,XX[86]Live birthNo visible abnormalities2220AMA, High risk of serum screening46,XXarr[hg19] Xp22.31p22.33 × 1 ~ 2 (32%)46,X.ish del(X)(p22.31)[38]/46,XX[62]Live birthShort stature(-2SD), dry skin2319 + 3History of adverse pregnancy46,XXarr[hg19] Xp22.31p22.33 × 1 ~ 2 (18%)46,X.ish del(X)(p22.31)[16]/46,XX[85]Live birthNo visible abnormalities Prenatal diagnosis and follow-up of 23 Turner mosaic fetuses who chose to continue pregnancy Embryonic demise (27 weeks) premature birth (34 weeks) TOP (26 weeks) Small for gestational age, oligohydramnios Discussion Individuals with Turner mosaicism possess one or more abnormal cell lines exhibiting either a complete or partial absence of an X chromosome, causing X chromosome haploinsufficiency and resulting in gene dosage effects. For genes that escape X-chromosome inactivation, their expression decreases to about half the normal levels [9]. These genes are crucial for regulating height, skeletal development, and ovarian function. Importantly, a subset of genes remains transcriptionally active even on the inactivated X chromosome [10]. Patients with Turner syndrome mosaicism typically exhibit less severe clinical manifestations compared to those with the 45,X karyotype [1]. The termination rate for non-mosaic Turner syndrome is approximately between 50% and 80% [11]. Some individuals may even develop normal secondary sexual characteristics and experience menarche, although they are prone to premature ovarian failure later in adulthood [11, 12]. The primary mechanism underlying the development of Turner mosaicism is the lagging of chromatids during mitotic anaphase in the early divisions of the fertilized egg, resulting in the loss of an X chromosome [13]. In patients with 45,X/46,XX mosaicism, a higher proportion of the normal cell line typically correlates with milder clinical symptoms [14]. In individuals with 45,X/47,XXX mosaicism, clinical manifestations can be relatively mild. This specific karyotype may lead to dosage compensation, potentially restoring normal ovarian function or even inducing precocious puberty. These effects are influenced by the interaction between the ovarian impairment from the 45,X cell line and the X chromosome dosage effect of the 47,XXX cell line [15]. The clinical presentation in cases of 45,X/46,XX/47,XXX mosaicism demonstrates significant variability, depending on the distribution and proportion of different cell lines across various tissues. If the 45,X cell line is predominant, patients may exhibit more characteristic features of Turner syndrome. However, a higher proportion of 47,XXX cells can lead to a milder phenotype, typically associated with trisomy X syndrome. Additionally, the presence of the 47,XXX cell line might result in mild cognitive impairments in some individuals [12]. The prenatal ultrasound phenotypes and clinical follow-up data from cases of X chromosome aneuploidy mosaicism detected in this study indicate that Turner syndrome mosaicism does not present specific prenatal features. This further emphasizes the necessity for meticulous postnatal monitoring of growth and development in cases with mosaicism levels exceeding 20%. The karyotype 45,X/46,XY often originates from a fertilized egg initially carrying a 46,XY karyotype, where the Y chromosome experiences lagging during anaphase in some cells during early cell division. Individuals with Turner mosaicism who also possess a Y chromosome lineage are at an increased risk of developing gonadoblastoma, with incidences reported as high as 30%, and the condition can manifest as early as 6 years of age [16]. In this study, two cases with 45,X/46,XY mosaicism, each having mosaicism levels below 10%, resulted in the birth of children who phenotypically appear normal. Follow-up assessments—one at 5 years and the other at 3 years and 4 months—show that both children display a normal female phenotype, suggesting a favorable prognosis for cases of low-level 45,X/46,XY mosaicism. Genes located in the pseudoautosomal region 1 (PAR1) on the X and Y chromosomes are believed to play a crucial role in the genetics of Turner syndrome. Many of these genes are highly dosage-sensitive, suggesting that cellular normality and viability depend on the presence of two functional copies of these genes. Typically, under normal physiological conditions, these genes are involved in genomic regulation [17, 18]. A crucial gene within the PAR1 region is the short stature homeobox-containing gene (SHOX), found on both sex chromosomes at locations Xp22.32 and Yp11.3. Recent research has confirmed that the short stature commonly seen in Turner syndrome patients is linked to disruptions in the SHOX gene. Deletions on the short arm of the X chromosome (Xp) that impact SHOX gene expression not only contribute to reduced stature but also can inhibit the proliferation of granulosa cells by decreasing the levels of genes involved in folliculogenesis, such as BMP15 [19]. The histone H3 lysine 27 demethylase KDM6A (UTX) manifests differential methylation patterns and significantly influences ovarian function and gonadal abnormalities by modulating genes essential for germ cell development and reproductive processes [20]. Additionally, the CSF2RA gene holds a pivotal role in proper placental development; its reduced expression is potentially linked with intrauterine fetal lethality [20]. Moreover, partial deletions or mosaicism affecting genes on the X chromosome, such as POF1A and FMR1, may impair the functioning of ovarian granulosa cells, subsequently hindering follicular development and hormone synthesis [21]. The prenatal ultrasound and follow-up data from patients with X chromosome structural abnormality mosaicism identified in this study indicate that there are discrepancies between prenatal and postnatal phenotypes in these individuals. Genital malformations and ovarian abnormalities are generally undetectable by prenatal ultrasound. Additionally, close monitoring of clinical phenotypic changes is necessary postnatally for cases with elevated mosaicism levels. Cardiovascular malformations are notably linked to Turner syndrome. It is estimated that approximately half of the asymptomatic patients with Turner syndrome exhibit underlying cardiovascular developmental abnormalities. Among these, coarctation of the aorta and partial anomalous pulmonary venous connection are common congenital defects [22]. These structural anomalies can lead to rare but potentially life-threatening complications such as aortic dilation, dissection, or rupture. The primary genetic basis for these conditions involves haploinsufficiency of specific genes on the X chromosome, including NLGN4X and VIPR2 [23]. This genetic deficiency disrupts the migration and function of neural crest cells, which are crucial for the normal development of the aortic valve and aortic arch. Additionally, this haploinsufficiency may lead to lymphatic dysplasia, presenting as nuchal cystic hygromas and edema. These lymphatic issues can compress the aortic arch, further predisposing to or exacerbating the severity of aortic coarctation [24]. Turner with 45,X exhibit the highest incidence of cardiovascular complications. Those with mosaicism have a relatively lower risk; however, higher degrees of mosaicism can be associated not only with structural heart defects but also with phenotypic abnormalities in other organs. These may include lymphedema, renal anomalies, and genitourinary abnormalities [25]. Intrauterine growth retardation (IUGR) is another characteristic feature of Turner mosaicism. Placental insufficiency and impaired angiogenesis in Turner mosaicism severely impact fetal development [26]. Furthermore, decreased expression of X-linked genes involved in cell proliferation, metabolism, and signal transduction can adversely affect overall fetal growth at the cellular level. This study identified 10 cases with abnormal ultrasound findings, including three cases of structural cardiac anomalies and two cases of intrauterine growth retardation. These findings indicate a possible link between prenatal intrauterine growth retardation, cardiac structural anomalies, and Turner syndrome mosaicism. Notably, one case, with the karyotype 45,X [24]/46,XX[76], presented with aortic coarctation, horseshoe kidney, and increased nuchal translucency (NT). Another case characterized by the karyotype 46,X, i(X)(q10)[66]/46,XX [24], exhibited a ventricular septal defect, left clubfoot, and widened lateral ventricles. These cases highlight multiple malformations, emphasizing the significant phenotypic variability observed in fetuses with Turner mosaicism. Tokita et al. compared the phenotypic data of 25 prenatally diagnosed patients with 45,X/46,XX mosaicism with that of 58 postnatally diagnosed patients with Turner syndrome mosaicism. The results showed that the prenatally diagnosed group was more likely to exhibit normal growth and development as well as normal secondary sexual characteristics, with a lower incidence of typical Turner syndrome features such as cardiovascular abnormalities and lymphedema, suggesting a relatively favorable clinical prognosis [27]. Previous detection of Turner mosaicism primarily in populations with specific clinical phenotypes may have overestimated its association with abnormal clinical presentations [28]. There are a large number of genes related to brain development and function on the X chromosome [29], some of which escape X chromosome inactivation and are expressed on both X chromosomes in normal female. When an X chromosome is missing, the expression levels of these genes will significantly decrease, thereby affecting neural development [30]. NLGN4X encodes a neural junction protein that plays a critical role in synaptic formation and function. The mutation of this gene is closely related to the autism spectrum and intellectual disabilities [31]. The absence of STS can lead to X-linked ichthyosis, but more importantly, STS is highly expressed in the brain and participates in the metabolism of neurosteroids. Neurosteroids are powerful neuromodulators that affect emotions, cognition, and social behavior. STS haploid deficiency is associated with social disorders, lack of concentration, and poor executive ability [32]. USP9X is a gene associated with neuronal survival, axonal development, and synaptic plasticity. Its abnormalities are related to intellectual disability and brain deformities [33]. The most typical case of Turner mosaic is ovarian dysplasia, but estrogen’s effects on the brain go far beyond reproduction. During critical developmental periods and throughout the lifespan, it has profound effects on the survival of neurons, the formation of synapses, the function of the hippocampus (related to memory), and the dopaminergic system [34]. Therefore, the mechanism underlying neurodevelopmental abnormalities in Turner syndrome mosaicism involves a multi-level and interconnected cascade. Follow-up in this study identified three cases (one 45,X [21]/46,XX[79], one 45,X [25]/46,XX[75], and one 45,X [25]/47,XXX[75]) with delayed speech and motor development, and one case (45,X [18]/46,XX[64]) with epilepsy. These findings underscore the necessity for close postnatal monitoring of neuropsychiatric development in cases where Turner mosaicism is identified prenatally. The main advantage of this study is that we conducted a comprehensive analysis of pregnancy information, mosaic karyotypes and frequency, ultrasound phenotype, and follow-up information of 92 prenatal Turner mosaic fetuses in a relatively large cohort. However, there are still some limitations. Firstly, the follow-up time varies, and the age of the follow-up subjects in this cohort is relatively young. Therefore, it is difficult to effectively evaluate the phenotype and diagnose neurodevelopmental abnormalities in some cases, especially for the secondary sexual characteristics closely related to Turner, which can only be evaluated after puberty. Secondly, although the sample size is larger than previous studies that focused on case reports, as a retrospective study, the data size is still limited, which may lead to biased conclusions. Conclusion The clinical severity of Turner mosaicism when diagnosed prenatally is influenced by both the degree of mosaicism and its distribution across tissues. Decisions regarding the termination of pregnancy should be made with caution in cases where mosaicism levels are below 30%, especially as fetuses with less than 10% mosaicism generally have a favorable prognosis. Prenatal ultrasound results for Turner mosaicism are generally nonspecific. Nonetheless, cardiovascular abnormalities and intrauterine growth restriction may be strongly linked to prenatal Turner mosaicism. When Turner syndrome mosaicism is identified prenatally but presents with normal ultrasound outcomes, it becomes critical to closely monitor the child’s neurodevelopment postnatally. Acknowledgements We would like to thank all the individuals and their families for participation and for agreeing to donate their personal data. Abbreviations Nuchal translucency Gestational week Single nucleotide polymorphism Fluorescence in situ hybridization Advanced maternal age Non-invasive prenatal testing Termination of pregnancy Not applicable Authors’ contributions All authors have materially participated in this study and manuscript preparation. Xiaojin Luo, Hongyan Niu and Fei Zhou collected all clinical data and carried out all the molecular and cytogenetic analyses. Yuanyuan Pei, Xiaoyi Cong and Shuangwu Li participated in the data analysis and drafted the manuscript. Jinmao Xu collected and analyzed ultrasound data. Liang Chang, Weiqiang Liu and Fengxiang Wei designed the work and drafted and revised the manuscript. All authors have approved the final article. Funding The study was supported by Shenzhen Science and Technology Plan Project (No. JCYJ20220530162412029), Key Clinical Projects of Peking University Third Hospital (No.BYSYZD2024010), National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital) (No.NCRC2025B06), and Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education (No.BYSYSZKF2023003). Data availability The datasets generated and/or analysed during the current study are not publicly available due to restrictions imposed by the ethics committee, but are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved (No. LGFYYXLL-028) by the Ethics Committee of Longgang District Maternity &Child Heathcare Hospital of Shenzhen City. All patients provided written informed consent for the use of their biological samples for research purposes, in accordance with Institutional Review Boards requirements and the Helsinki’s declaration. Consent for publication Consent for publication has been obtained from the patient and/or their legal guardians. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Liang Chang, Email: changliangchina@163.com. Weiqiang Liu, Email: liuwq06@126.com. Fengxiang Wei, Email: weifengxiang1115@outlook.com. References Associated Data Data Availability Statement The datasets generated and/or analysed during the current study are not publicly available due to restrictions imposed by the ethics committee, but are available from the corresponding author on reasonable request.